![]() ![]() This means that the device itself can collect ECG recordings and send them wirelessly to physicians without the need for an intermediate device such as a phone. ![]() The RhythmStar cardiac monitor, a new wearable ECG monitoring device from RhythMedix, has built-in cellular connectivity. Typically, the ECG recordings from these devices are sent to a nearby cellular device such as a smart phone, where an application collects and reads the ECG recordings and, in some cases, transmits them to physicians wirelessly. On the other hand, some devices are manufactured specifically for this purpose, such as AliveCor’s Kardia device. ![]() This capability has even been incorporated into more generic devices for instance, Apple’s SmartWatch has been FDA-approved to take clinical-grade ECG recordings and detect atrial fibrillation. There are a number of wearable devices that detect heart arrhythmias via electrocardiogram (ECG) monitoring. It is important to diagnose and treat heart arrhythmias early because, if left untreated, they can lead to heart failure or, in some cases, even sudden cardiac death. Heart rhythm issues, or “arrhythmias,” may affect as many as 2% of adults.Īs of 2021, GlobalData estimates that atrial fibrillation (a specific type of arrhythmia) affects nearly four million Americans. In the cardiology space, a common application for wearable technology is heart rhythm monitoring. While historically utilised mainly for fitness tracking, the usage of wearable technology has been steadily growing in the healthcare field. In healthcare, “wearable technologies” refers to non-invasive devices that capture, analyse, and aggregate physiological data to improve personal health and well-being. ![]() This device boasts cellular connectivity and joins a roster of wearable cardiac devices already available on the market. 1,2 While remote cardiac monitoring has improved arrhythmia detection, patient compliance and timely access to heart activity remain a challenge with currently available competitive monitoring technologies.On 18 February 2021, RhythMedix announced the launch of its newest-generation wearable cardiac monitor, the RhythmStar. Atrial fibrillation (AFib) is the most frequent cardiac arrhythmia and a major risk factor for ischemic stroke. Heart arrhythmias are a major health concern and double the risk of death in an estimated 37.5 million people worldwide. In addition to the new Extended Wear Holter option, RhythMedix offers multiple modalities including mobile cardiac telemetry. The RhythmStar platform fits seamlessly into clinical practice and its interoperability support easily integrates with electronic medical record (EMR) systems. Unlike these systems, RhythmStar instantly transfers data wirelessly to enable faster ECG analysis with rapid report turnaround, so that care providers receive diagnostic reporting weeks faster than with mail back data retrieval methods. "We've monitored over 1 million patients and look forward to accelerating adoption of our innovative remote cardiac monitoring solution to reach even more patients."Īlternative monitoring systems require patients to send the wearable device back to the manufacturer for manual data retrieval, analysis and report generation. RhythMedix is committed to transforming and simplifying the diagnostic pathway to enable faster diagnosis, without missing a beat," stated Brian Pike, President, of RhythMedix. "We are especially pleased to launch expanded capabilities so close to National AFib Awareness Month. ![]()
0 Comments
Leave a Reply. |